<?xml version="1.0" encoding="UTF-8"?>
<p>We collected blood for HCV‐RNA levels at weeks 4, 12, and 24 and a CBC and CMP at weeks 4, 8, and 12, consistent with the American Association for the Study of Liver Disease (AASLD) guidelines at the time of study initiation in 2015.
 <xref rid="hep41482-bib-0012" ref-type="ref">12</xref> However, study personnel involved in the care of SHARED‐2 participants did not have access to any of the on‐treatment laboratory results (i.e., laboratory results from weeks 4, 8, and 12). The on‐treatment laboratory results were only accessible by the independent lab monitor. The results were then entered into a limited‐access field of the study database for later analysis.
</p>
